Table 2.
Means (SD) of NIT scores and associated biomarker levels in the matched cohort by age group.
| ≤45 years |
46–55 years |
56–64 years |
≥65 years |
p values | |||||
|---|---|---|---|---|---|---|---|---|---|
| n | Value | n | Value | n | Value | n | Value | ||
| NIS2+TM | |||||||||
| NIS2+™∗ | 177 | 0.56 (0.28) | 177 | 0.56 (0.28) | 177 | 0.55 (0.26) | 177 | 0.57 (0.28) | 0.7111 |
| miR34-a, FoldC† | 177 | 1.31 (1.96) | 177 | 1.19 (1.57) | 177 | 0.9 (0.90) | 177 | 0.95 (1.04) | 0.1138 |
| YKL-40, ng/ml† |
177 |
63.98 (60.36) |
177 |
90.58 (149.54) |
177 |
95.93 (121.46) |
177 |
117.01 (107.43) |
<0.0001 |
| FIB-4/NFS/APRI | |||||||||
| FIB-4† | 177 | 0.92 (0.62) | 177 | 1.38 (0.89) | 177 | 1.52 (0.75) | 177 | 2.04 (1.04) | <0.0001 |
| NFS | 177 | –2.28 (1.42) | 177 | –1.36 (1.41) | 177 | –0.96 (1.16) | 177 | –0.27 (1.15) | <0.0001 |
| APRI† | 177 | 0.55 (0.63) | 177 | 0.58 (0.54) | 177 | 0.48 (0.29) | 177 | 0.56 (0.39) | 0.1891 |
| AST, IU/L† | 177 | 45.61 (37.58) | 177 | 43.49 (33.9) | 177 | 36.97 (17.86) | 177 | 39.92 (23.06) | 0.273 |
| ALT, IU/L† | 177 | 68.78 (52.55) | 177 | 58.56 (42.59) | 177 | 50.31 (27.05) | 177 | 48.92 (31.03) | 2e-04 |
| Platelets, 10e9/L | 177 | 252.84 (65.91) | 177 | 232.08 (67.47) | 177 | 225.31 (59.85) | 177 | 208.87 (58.16) | <0.0001 |
| FPG, mmol/L† | 176 | 5.94 (2.08) | 177 | 6.08 (1.80) | 176 | 6.23 (1.87) | 177 | 6.18 (1.73) | 0.1841 |
| Albumin, g/L |
177 |
46.27 (3.32) |
177 |
45.99 (3.06) |
177 |
45.81 (2.87) |
177 |
44.97 (3.02) |
7e-04 |
| ELF™ | |||||||||
| ELF™ | 177 | 8.94 (1.02) | 177 | 9.44 (0.97) | 177 | 9.66 (0.86) | 177 | 10.06 (1.02) | <0.0001 |
| Hyaluronic acid, ng/ml† | 177 | 38.65 (50.93) | 177 | 70.82 (156.35) | 177 | 79.81 (78.45) | 177 | 126.76 (155.42) | <0.0001 |
| P3NP, ng/ml† | 177 | 10.85 (5.54) | 177 | 11.37 (6.36) | 177 | 10.67 (4.91) | 177 | 12.14 (6.37) | 0.0774 |
| TIMP1, ng/ml† |
177 |
265.2 (72.52) |
177 |
264.05 (73.86) |
177 |
267.81 (63.35) |
177 |
275.74 (85.77) |
0.5791 |
| Other biomarkers | |||||||||
| AST/ALT ratio† | 177 | 0.72 (0.30) | 177 | 0.78 (0.28) | 177 | 0.79 (0.24) | 177 | 0.88 (0.34) | <0.0001 |
| A2M, g/L | 176 | 2.09 (0.85) | 170 | 2.14 (0.79) | 172 | 2.47 (0.92) | 176 | 2.68 (0.86) | <0.0001 |
| HbA1c, % | 174 | 6.12 (1.07) | 177 | 6.16 (0.92) | 174 | 6.22 (0.99) | 177 | 6.2 (0.87) | 0.7915 |
| GGT, IU/L† | 177 | 91.88 (131.22) | 177 | 76.4 (100.73) | 177 | 75.36 (88.19) | 177 | 81.98 (110.86) | 0.2114 |
| ALP, IU/L† | 176 | 84.64 (38.34) | 177 | 81.73 (31.60) | 177 | 87.35 (26.68) | 177 | 85.74 (29.57) | 0.1168 |
| Triglycerides, mmol/L† | 177 | 2.46 (2.31) | 177 | 2.09 (3.14) | 177 | 2.05 (1.31) | 177 | 1.81 (0.81) | 0.0214 |
| Total cholesterol, mmol/L | 177 | 4.92 (1.14) | 177 | 4.71 (1.23) | 177 | 4.66 (1.10) | 176 | 4.59 (1.10) | 0.0344 |
Matched cohort, n = 708. p values were calculated using Welch-adapted one-way ANOVA tests based either on raw or transformed (log10 or logit) data for biomarkers and NITs that were associated to a Skewness score >2 and/or a Kurtosis score >7.
A2M, alpha-2-macroglobulin; ALP, alkaline phosphatase; ALT, alanine aminotransferase; APRI, aspartate aminotransferase-to-platelet ratio index; AST, aspartate aminotransferase; ELF™, Enhanced Liver Fibrosis; FIB-4, Fibrosis-4; FPG, fasting plasma glucose; GGT, γ-glutamyl transferase; HbA1c, glycated hemoglobin; MAS, MASLD activity score; MASLD, metabolic dysfunction-associated liver disease; miR34-a, microRNA 34a; NAFLD, non-alcoholic fatty liver disease; NFS, NAFLD fibrosis score; NIT, non-invasive test; P3NP, type III procollagen peptide; TIMP1, tissue inhibitor matrix metalloproteinase 1.
Logit-transformed for computation of p values.
Log-transformed (base 10) for computation of p values.